Present state of new chiral drug development and review in Japan

Journal of Health Science

Volumn 54, Issue 1, 2008, Pages 23-29

  Shimazawa, Rumiko ^a   Nagai, Naomi ^b   Toyoshima, Satoshi ^b   Okuda, Haruhiro ^c  

^a DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^b PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Chiral drug; Guideline; Pharmaceutical development; Racemic drug; Single enantiomer drug

Indexed keywords

NEW DRUG;

ARTICLE; CHIRALITY; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG QUALITY; DRUG RESEARCH; DRUG SYNTHESIS; ENANTIOMER; HUMAN; ISOMER; JAPAN; NONHUMAN; PRACTICE GUIDELINE; RACEMIC MIXTURE; STEREOCHEMISTRY;

EID: 44449126537     PISSN: 13449702     EISSN: 13475207     Source Type: Journal    
DOI: 10.1248/jhs.54.23     Document Type: Article

References (16)

1. The United States Adopted Names (USAN) Council in The American Medical Association (AMA) (2005) Geometric isomerism and chirality: The USAN perspective, http://www.amaassn.org/ama/pub/category/15698.html
2. Stinson, S. (1998) Counting on chirality. Chem. Eng. News, 76(38), 83-104.
3. Rouhi, A. M. (2003) Chiral business. Chem. Eng. News, 81(18), 45-55.
4. Ministry of Health, Labour and Welfare (1961) Enforcement Regulations of the Pharmaceutical Affairs Law, Article 38, http://law.e-gov.go.jp/ htmldata/S36/S36F03601000001.html
5. Pharmaceuticals and Medical Devices Agency (April 2001-present) Information for approved drugs in Japan, http://www.info.pmda.go.jp/ shinyaku/shinyaku index.html
6. Pharmaceuticals and Medical Devices Agency (September 1999-October 2005) Information for approved drugs in Japan, http://www.jpec.or.jp/contents/ c01/link.html
7. Food and Drug Administration (1992) FDA's policy statement for the development of new stereoisomeric drugs. US Food and Drug Administration regulatory guidance, http://www.fda.gov/cder/guidance/stereo.htm
8. Health Canada (2000) Stereochemical issues in chiral drug development. Health Canada guidance document, http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-ld/chem/stereoe.html
9. European Medicines Agency (1997) Investigation of chiral active substances European Union Guidelines, http://www.emea.europa.eu/pdfs/human/ qwp/3cc29aen.pdf
10. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceutical Human Use (1999) Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances, Q6A, Step 4, ICH, http://www.ich.org/cache/ compo/363-272-1.html#Q6A
11. Ministry of Health, Labour and Welfare (2001) Setting of Specifications and Test Methods of New Drugs, Notification No.568 of the Evaluation and Licensing Division, PMSB dated May 1, 2001, http://www.pmda.go. jp/ich/q/q6a 01 5 1.pdf
12. Ministry of Health and Welfare (1994) Guidelines for Establishment of Specifications and Test Methods for New Drugs, Notification No. 586 of the Pharmaceuticals and Cosmetics Division, PAB dated September 1, 1994.
13. Branch, S. K. (2001) International regulation of chiral drugs. In Chiral Separation Techniques. A Practical Approach, 2nd Edition (Subramanian, G., Ed.) Wiley-VCH, Weinheim, pp. 319-342.
14. Shindo, H. and Caldwell, J. (1995) Development of chiral drugs in Japan: an update on regulatory and industrial opinion. Chirality, 7, 349-352.
15. Shindo, H. and Caldwell, J. (1991) Regulatory aspects of the development of chiral drugs in Japan: a status report. Chirality, 3, 91-93.
16. Ministry of Health, Labour and Welfare (1998) Guidelines on Non-clinical Pharmacokinetic Studies, Notification No. 496 of the Evaluation and Licensing Division, PMSB dated June 26, 1998, http://www.nihs.go.jp/mhlw/ tuuchi/1998/980626/980626.pdf